Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s first homegrown innovative HIV therapy, has been approved. The approval allows the drug to be administered via intravenous bolus, significantly reducing the administration time.
Alfusid: World’s First Long-Acting HIV Drug
Alfusid is described as the world’s first long-acting HIV drug. It is a cell fusion inhibitor that prevents HIV from fusing with healthy cells. The molecule is designed to bind strongly to human blood protein albumin, extending its half-life and enabling once-weekly or biweekly dosing by intravenous infusion. This innovative approach offers a more convenient treatment option for patients with HIV.
Market Approvals and Recognition
Alfusid obtained market approval in May 2018 for use in HIV-1 infected individuals who still have virus replication after antiviral treatment, combined with other antiretroviral drugs in China. The drug was included in the National Reimbursement Drug List (NRDL) in 2020, enhancing its accessibility to patients. In February of this year, Ecuador became the first country in Latin America to approve the drug, further expanding its global reach.
Future Outlook
The new approval for intravenous bolus administration underscores Frontier Biotechnologies’ commitment to improving the treatment experience for patients with HIV. With its extended half-life and convenient dosing schedule, Alfusid offers a significant advancement in the management of HIV, potentially improving patient adherence and outcomes.-Fineline Info & Tech
